参考文献/References:
[1] Cooper DS,Doherty GM,Haugen BR,et al.Management guidelines for patients with thyroid nodules and differentiated thyroid cancer.Thyroid,2006,16(2):109-142.
[2] Salvatore B,Paone G,Klain M,et al.Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.Q J Nucl Med Mol Imaging,2008,52(1):2-8.
[3] Mausberg R,Crawford B,Uren RF,et al.Minimally invasive radioguided surgery for recurrent thyroid cancer using iodine-123.Clin Nucl Med,2005,30(1):43-44.
[4] Fujie S,Okumura Y,Sato S,et al.Diagnostic capabilities of I-131,Tl-201,and Tc-99m-MIBI scintigraphy for metastatic differentiated thyroid carcinoma after total thyroidectomy.Acta Med Okayama,2005,59(3):99-107.
[5] Noh JY.Predictive value of serum thyroglobulin and diagnostic imaging in post-surgical follow-up of differentiated thyroid cancer.Nippon Riusho,2007,65(11):2069-2072.
[6] Moretti JL,Hauet N,Caglar M,et al.To use MIBI or not to use MIBI? That is the question when assessing tumour cells.Eur J Nucl Med Mol Imaging,2005,32(7):836-842.
[7] Miyamoto S,Kanji K,Misaki T,et al.Evaluation of technetium-99m-MIBI scintigraphy in metastatic differentiated thyroid carcinoma.J Nucl Med,1997,38(3):352-356.
[8] Ronga G,Ventroni G,Montesano T,et al.Sensitivity of[99mTc]methoxyisobutylisonitrile scan in patients with metastatic differentiated thyroid cancer.Q J Nucl Med Mol Imaging,2007,51(4):364-371.
[9] Wong KT,Choi PT,Lee YY,et al.Current role of radionuclide imaging in differentiated thyroid cancer.Cancer Imaging,2008,10(8):159-162.
[10] Zuijdwijk MD,Vogel WV,Corsteus FH,et al.Utility of fluoredeoxyglucose-PET in patients with differentiated thyroid carcinoma.Nucl Med Commun,2008,29(7):636-641.
[11] Fujie S,Okumura Y,Sato S,et al.Diagnostic capabilities of I-131 T1-201 and Tc-99m-MIBI scintigraphy for metastatic differentiated thyroid carcinoma after total thyroidectomy.Acta Med Okayama,2005,59(3):99-107.
[12] Hsu CH,Liu FY,Yen RF,et al.Tc-99m MIBI SPECT in detecting metastatic papillary thyroid carcinoma in patients with elevated human serum thyroglobulin levels hut negative I-131 whole body scan.Endocr Res,2003,29(1):9-15.
[13] Wu HS,Huang WS,Liu YC,et al.Comparison of FDG-PET and technetium-99m MIBI SPECT metastatic cervical lymph nodes in well-differentiated thyroid carcinoma with elevated serum HTG but negative I-131 whole body scan.Anticancer Res,2003,23(5b):4235-4238.
[14] Kücük ON,Gültekin SS,Aras G,et al.Radioiodine whole-body scans,thyroglabulin levels,99Tcm-MIBI scans and computed tomography:results in patients with lung metastases from differentiated thyroid cancer.Nucl Med Commun,2006,27(3):261-266.
[15] Miller DD,Heyl BL,Walsh RA.Lung uptake of technetium-99m hexamibi isonitrile during acute reversible ischemie left vantricular dysfunction in conscious dogs.Circulation,1988,78(suppl):Ⅱ-387.
[16] Rubello D,Piotto A,Pagetta C,et al.(99m)Tc-MIBI radio-guided surgery for recurrent thyroid carcinoma:technical feasibility and procedure,and preliminary clinical results.Eur J Nucl Med Imaging,2002,29(9):1201-1205.
[17] Casara D,Rubello D,Saladini G,et al.Different features of pulmonary metastases in differetiated thyroid cancer:natural history and multivariate statistical analysis of prognostic variables.J Nucl Med,1993,34(10):1626-1631.
[18] 高克加,王建华,叶智卫,等.99mTc-MIBI显像对甲状腺癌疗效的评估价值.上海医学,2002,25(2):89-91.
[19] 王玉君,赵彦辉,崔亚利.99mTc-MIBI全身显像在治疗分化型甲状腺癌转移灶中的应用价值.实用肿瘤学杂志,2008(4):337-338.
[20] 高识,马庆杰,孙辉,等.99Tcm-甲氧基异丁基异腈(MIBI)显像与甲状腺癌远处转移的关系研究.中国老年学杂志,2006,26(9):1196-1197.
[21] 王强,余永利,高秀丽,等.甲状腺癌术后患者颈淋巴结转移影像学比较研究.上海交通大学学报:医学版,2009,29(9):1085-1087.
[22] Rubello D,Salvatori M,Pelizzo MR,et al.Radio-guided surgery of differentiated thyroid cancer using(131)I or 99mTc-sestamibi.Nucl Med Commum 2006,27(1):1-4.
[23] Rubello D,Pelizzo MR,Casara D,et al.Radio-guided surgery for non-131I-avid thyroid cancer.Thyroid,2006,16(11):1105-1111.
相似文献/References:
[1]李盼丽,宋少莉.碘难治性分化型甲状腺癌靶向药物治疗进展[J].国际放射医学核医学杂志,2016,40(3):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
Li Panli,Song Shaoli.Radioactive iodine refractory differentiated thyroid cancer targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
[2]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[3]陈立,陈跃.分化型甲状腺癌骨转移诊断及疗效评价的核素显像研究进展[J].国际放射医学核医学杂志,2016,40(6):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
Chen Li,Chen Yue.Diagnosis and evaluation of curative effect progress of radionuclide imaging methods in differentiated thyroid cancer of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
[4]惠金子,赵德善.Tg、TgAb及TSH在分化型甲状腺癌术前的预测分析[J].国际放射医学核医学杂志,2015,39(2):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
Hui Jinzi,Zhao Deshan.The prediction of risk of differentiated thyroid carcinoma with preoperative serum thyroid stimulating hormone, thyrogiobulin and antithyroglobulin antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
[5]刘斌,潘明志.BRAF基因突变对甲状腺乳头状癌诊治价值的研究进展[J].国际放射医学核医学杂志,2015,39(2):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
Liu Bin,Pan Mingzhi.Advances in value of BRAF gene mutation on the diagnosis and treatment of papillary thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
[6]胡斌,王锦锋,毛秋粉.18F-FDG PET/CT显像在Tg阳性131I全身显像阴性的分化型甲状腺癌患者中的应用价值[J].国际放射医学核医学杂志,2015,39(3):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
Hu Bin,Wang Jinfeng,Mao Qiufen.The application value of 18F-FDG PET/CT in patients with differentiated thyroid cancer of high thyroglobulin level and negative 131I whole body scan[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
[7]刘鹏杰,唐铭,邓智勇,等.131I治疗儿童分化型甲状腺癌期间出现低钙血症伴癫痫发作一例[J].国际放射医学核医学杂志,2015,39(4):352.[doi:10.3760/cma.j.issn.1673-4114.2015.04.017]
[8]寇莹,刘建中,郝新忠,等.甲状腺癌131I治疗后全身扫描盆腔浓聚131I的临床分析[J].国际放射医学核医学杂志,2014,38(1):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
Kou Ying,Liu Jianzhong,Hao Xinzhong,et al.Analysis of pelvic 131I uptake after 131I whole body scan in patients with thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
[9]李敬彦,蒋宁一.分化型甲状腺癌术后131I清甲治疗方法的相关问题[J].国际放射医学核医学杂志,2014,38(1):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
Li Jingyan,Jiang Ningyi.Issues related to radioactive iodine ablation in patients with differentiated thyroid carcinoma under-going thyroid surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
[10]成钊汀,谭建.分化型甲状腺癌术后患者131I治疗的辐射剂量与防护[J].国际放射医学核医学杂志,2014,38(2):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
Cheng Zhaoting,Tan Jian.Radiation dose and protection of differentiated thyroid carcinoma postoperative patients with 131I treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(5):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]